Polymeric trileaflet prosthetic heart valves: Evolution and path to clinical reality

Expert Review of Medical Devices

Volumn 9, Issue 6, 2012, Pages 577-594

  Claiborne, Thomas E ^a   Slepian, Marvin J ^a,b   Hossainy, Syed ^c   Bluestein, Danny ^a  

^a St Francis Hospital The Heart Center   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c ABBOTT VASCULAR   (United States)

Author keywords

aortic stenosis; device thrombogenicity emulation; nano composite; platelet activation; polyurethane; SIBS; transcatheter valve replacement

Indexed keywords

AORTIC STENOSIS; PLATELET ACTIVATION; SIBS; THROMBOGENICITY; VALVE REPLACEMENT;

BIOMINERALIZATION; DISEASES; POLYURETHANES; PROSTHETICS; TISSUE; VALVES (MECHANICAL);

POLYMERS;

BIOPOLYMER; NANOCOMPOSITE; POLYMER; POLYURETHAN;

AORTA STENOSIS; AORTA VALVE REPLACEMENT; COMPUTATIONAL FLUID DYNAMICS; DACRON VASCULAR PROSTHESIS; HEART VALVE PROSTHESIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOGENICITY; TRANSCATHETER AORTIC VALVE IMPLANTATION;

AORTIC VALVE; CARDIAC CATHETERIZATION; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; POLYMERS; PROSTHESIS DESIGN;

PROSPECT HILL VIRUS;

EID: 84871362140     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.12.51     Document Type: Review

References (122)

1. Rosamond W, Flegal K, Friday G et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (5), e69-e171 (2007).
2. Kurtz CE, Otto CM. Aortic stenosis: clinical aspects of diagnosis and management, with 10 illustrative case reports from a 25-year experience. Medicine (Baltimore) 89(6), 349-379 (2010).
3. Chandran KB, Rittgers SE, Yoganatha AP. Biofuid Mechanics: The Human Circulation. CRC/Taylor & Francis, FL, USA, 419 (2007).
4. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcifcation: basic science to clinical practice. Heart 95(8), 616-623 (2009).
5. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active atheroinfammatory process. Curr. Opin. Lipidol. 18(5), 483-491 (2007).
6. Hermans H, Herijgers P, Holvoet P et al. Statins for calcifc aortic valve stenosis: into oblivion after SALTIRE and SEAS? An extensive review from bench to bedside. Curr. Probl. Cardiol. 35(6), 284-306 (2010).
7. Rajamannan NM, Evans FJ, Aikawa E et al. Calcifc aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcifc aortic valve disease-2011 update. Circulation 124(16), 1783-1791 (2011).
8. Parolari A, Loardi C, Mussoni L et al. Nonrheumatic calcifc aortic stenosis: an overview from basic science to pharmacological prevention. Eur. J. Cardiothorac. Surg. 35(3), 493-504 (2009).
9. Holmes DR Jr, Mack MJ, Kaul S et al.; American College of Cardiology Foundation; American Association for Thoracic Surgery; Society for Cardiovascular Angiography and Interventions; Society for Thoracic Surgeons; American Heart Association; American Society of Echocardiography; European Association for Cardio-Thoracic Surgery; Heart Failure Society of America; Mended Hearts; Society of Cardiovascular Anesthesiologists; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcath-eter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Ann. Thorac. Surg. 93(4), 1340-1395 (2012).
10. Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J. Am. Coll. Cardiol. 55(22), 2413-2426 (2010).
11. McClure RS, Narayanasamy N, Wiegerinck E et al. Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients. Ann. Thorac. Surg. 89(5), 1410-1416 (2010).
12. Chaudhry MA, Raco L, Muriithi EW, Bernacca GM, Tolland MM, Wheatley DJ. Porcine versus pericardial bioprostheses: eleven-year follow up of a prospective randomized trial. J. Heart Valve Dis. 9(3), 429-437; discussion 437 (2000).
13. Walther T, Falk V, Mohr FW. Minimally invasive surgery for valve disease. Curr. Probl. Cardiol. 31(6), 399-437 (2006).
14. Rosengart TK, Feldman T, Borger MA et al.; American Heart Association Council on Cardiovascular Surgery and Anesthesia; American Heart Association Council on Clinical Cardiology; Functional Genomics and Translational Biology Interdisciplinary Working Group; Quality of Care and Outcomes Research Interdisciplinary Working Group. Percutaneous and minimally invasive valve procedures: a scientifc statement from the American Heart Association Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology, Functional Genomics and Translational Biology Interdisciplinary Working Group, and Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 117(13), 1750-1767 (2008).
15. Andersen HR. History of percutaneous aortic valve prosthesis. Herz 34(5), 343-346 (2009).
16. Kidane AG, Burriesci G, Cornejo P et al. Current developments and future prospects for heart valve replacement therapy. J. Biomed. Mater. Res. Part B Appl. Biomater. 88(1), 290-303 (2009).
17. Bower JL, Christensen CM. Disruptive technologies-catching the wave. Harv. Bus. Rev. 73, 43-53 (1995).
18. Webb J, Cribier A. Percutaneous trans-arterial aortic valve implantation: what do we know? Eur. Heart J. 32(2), 140-147 (2011).
19. Davies H. Catheter-mounted valve for temporary relief of aortic insuffciency. Lancet 1, 250 (1965).
20. Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of artifcial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur. Heart J. 13(5), 704-708 (1992).
21. Cribier A, Eltchaninoff H, Bash A et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcifc aortic stenosis: frst human case description. Circulation 106(24), 3006-3008 (2002).
22. Bonhoeffer P, Boudjemline Y, Saliba Z et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 356 (9239), 1403-1405 (2000).
23. Azadani AN, Tseng EE. Transcatheter valve-in-valve implantation for failing bioprosthetic valves. Future Cardiol. 6(6), 811-831 (2010).
24. Gurvitch R, Cheung A, Ye J et al Transcatheter valve-in-valve implantation for failed surgical bioprosthetic valves. J. Am. Coll. Cardiol. 58(21), 2196-2209 (2011).
25. Greif M, Lange P, Mair H et al Transcatheter Edwards Sapien XT valve in valve implantation in degenerated aortic bioprostheses via transfemoral access. Clin. Res. Cardiol. doi:10.1007/s00392-012-0488-3 (2012) (Epub ahead of print).
26. Toggweiler S, Wood DA, Rodés-Cabau J et al. Transcatheter valve-in-valve implantation for failed balloon-expandable transcatheter aortic valves. JACC Cardio-vasc. Interv. 5(5), 571-577 (2012).
27. Willson AB, Rodès-Cabau J, Wood DA et al. Transcatheter aortic valve replacement with the St. Jude Medical Portico valve: frst-in-human experience. J. Am. Coll Cardiol. 60(7), 581-586 (2012).
28. Zegdi R, Bruneval P, Blanchard D, Fabiani JN. Evidence of leafet injury during percutaneous aortic valve deployment. Eur. J. Cardiothorac. Surg. 40(1), 257-259 (2011).
29. de Buhr W, Pfeifer S, Slotta-Huspenina J, Wintermantel E, Lutter G, Goetz WA. Impairment of pericardial leafet structure from balloon-expanded valved stents. J. Thorac. Cardiovasc. Surg. 143(6), 1417-1421 (2012).
30. Hufnagel CA. Plastic cardiac valvular prostheses. Am. J. Med. 11, 243-243 (1951).
31. Miller BJ, Gibbon JH Jr, Greco VF, Smith BA, Cohn CH, Allbritten FF Jr. The production and repair of interatrial septal defects under direct vision with the assistance of an extracorporeal pump-oxygenator circuit. J. Thorac. Surg 26(6), 598-616; discussion 631 (1953).
32. Gott VL, Alejo DE, Cameron DE. Mechanical heart valves: 50 years of evolution. Ann. Thorac. Surg 76(6), S2230-S2239 (2003).
33. Ross DN. Homograft replacement of the aortic valve. Lancet 2(7254), 487 (1962).
34. Kaiser GA, Hancock WD, Lukban SB, Litwak RS. Clinical use of a new design stented xenograft heart valve prosthesis. Surg. Forum 20, 137-138 (1969).
35. Carpentier A. From valvular xenograft to valvular bioprosthesis (1965-1977). Med. Instrum. 11(2), 98-101 (1977).
36. Carpentier A. From valvular xenograft to valvular bioprosthesis: 1965-1970. Ann. Thorac. Surg 48(3 Suppl.) S73-S74 (1989).
37. Ten Berge L. A fexible cardiac valve prosthesis; preliminary report on the development of an experimental valvular prosthesis. Arch. Chir. Neerl. 10(1), 26-33 (1958).
38. Elliot EC, Callaghan JC. All plastic ventricle-type pump with tricuspid valves. Can. J. Surg 1(4), 308-312 (1958).
39. Braunwald NS, Cooper T, Morrow AG. Complete replacement of the mitral valve. Successful clinical application of a fexible polyurethane prosthesis. J. Thorac. Cardiovasc. Surg 40, 1-11 (1960).
40. Maisano F, La Canna G, Colombo A, Alferi O. The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique. J. Am. Coll. Cardiol. 58(21), 2174-2182 (2011).
41. Ghanbari H, Viatge H, Kidane AG, Burriesci G, Tavakoli M, Seifalian AM. Polymeric heart valves: new materials, emerging hopes. Trends Biotechnol. 27(6), 359-367 (2009).
42. Kütting M, Roggenkamp J, Urban U, Schmitz-Rode T, Steinseifer U. Polyurethane heart valves: past, present and future. Expert Rev. Med. Devices 8(2), 227-233 (2011).
43. Mori H, Hessel EA 2nd, Nelson RJ, Anderson HN, Dillard DH, Merendino KA. Design and durability test of Silastic trileafet aortic valve prostheses. J. Thorac. Cardiovasc. Surg. 65(4), 576-582 (1973).
44. Imamura E, Kaye MP. Function of expanded-polytetrafuoroethylene laminated trileafet valves in animals. Mayo Clin. Proc. 52(12), 770-775 (1977).
45. Wisman CB, Pierce WS, Donachy JH, Pae WE, Myers JL, Prophet GA. A polyurethane trileafet cardiac valve prosthesis: in vitro and in vivo studies. Trans. Am. Soc. Artif. Intern. Organs 28, 164-168 (1982).
46. Kiraly R, Yozu R, Hillegass D et al. Hexsyn trileafet valve: application to temporary blood pumps. Artif. Organs 6(2), 190-197 (1982).
47. Woo YR, Williams FP, Yoganathan AP. Steady and pulsatile fow studies on a trileafet heart valve prosthesis. Scand. J. Thorac. Cardiovasc. Surg. 17(3), 227-236 (1983).
48. Woo YR, Williams FP, Yoganathan AP. In-vitro fuid dynamic characteristics of the abiomed trileafet heart valve prosthesis. J. Biomech. Eng. 105(4), 338-345 (1983).
49. Hilbert SL, Ferrans VJ, Tomita Y, Eidbo EE, Jones M. Evaluation of explanted polyurethane trileafet cardiac valve prostheses. J. Thorac. Cardiovasc. Surg. 94 (3), 419-429 (1987).
50. Chandran KB, Fatemi R, Schoephoerster R et al. In vitro comparison of velocity profles and turbulent shear distal to polyurethane trileafet and pericardial prosthetic valves. Artif. Organs 13(2), 148-154 (1989).
51. Chandran KB, Schoephoerster RT, Wurzel D et al. Hemodynamic comparisons of polyurethane trileafet and bioprosthetic heart valves. ASAIO Trans. 35(2), 132-138 (1989).
52. Nistal F, García-Martínez V, Arbe E et al. In vivo experimental assessment of polytetrafuoroethylene trileafet heart valve prosthesis. J. Thorac. Cardiovasc. Surg. 99 (6), 1074-1081 (1990).
53. Corden J, David T, Fisher J. The infuence of open leafet geometry on the haemody-namic fow characteristics of polyurethane trileafet artifcial heart valves. Proc. Inst. Mech. Eng. H. 210(4), 273-287 (1996).
54. Wheatley DJ, Bernacca GM, Tolland MM, O'Connor B, Fisher J, Williams DF. Hydrodynamic function of a biostable polyurethane fexible heart valve after six months in sheep. Int. J. Artif. Organs 24(2), 95-101 (2001).
55. Leo HL, Simon H, Carberry J, Lee SC, Yoganathan AP. A comparison of fow feld structures of two tri-leafet polymeric heart valves. Ann. Biomed. Eng. 33(4), 429-443 (2005).
56. Pinchuk L, Wilson GJ, Barry JJ, Schoephoerster RT, Parel JM, Kennedy JP. Medical applications of poly(styrene-block-isobutylene-block-styrene) ('SIBS'). Biomaterials 29(4), 448-460 (2008).
57. Dalmau MJ, Maríagonzález-Santos J, López- Rodríguez J, Bueno M, Arribas A. The Carpentier-Edwards Perimount Magna aortic xenograft: a new design with an improved hemodynamic performance. Interact. Cardiovasc. Thorac. Surg 5(3), 263-267 (2006).
58. Stevenson DM, Yoganathan AP. Numerical simulation of steady turbulent fow through trileafet aortic heart valves-I. Computational scheme and methodology. J. Biomech. 18(12), 899-907 (1985).
59. Stevenson DM, Yoganathan AP, Williams FP. Numerical simulation of steady turbulent fow through trileafet aortic heart valves-II. Results on fve models. J. Biomech. 18(12), 909-926 (1985).
60. De Hart J, Peters GW, Schreurs PJ, Baaijens FP. A three-dimensional computational analysis of fuid-structure interaction in the aortic valve. J. Biomech. 36(1), 103-112 (2003).
61. Carmody CJ, Burriesci G, Howard IC, Patterson EA. An approach to the simulation of fuid-structure interaction in the aortic valve. J. Biomech. 39(1), 158-169 (2006).
62. Peskin CS, Mcqueen DM. A 3-dimen-sional computational method for blood-fow in the heart. 1. Immersed elastic fbers in a viscous incompressible fuid. J. Comput. Phys. 81, 372-405 (1989).
63. Schoephoerster RT, Chandran KB. Velocity and turbulence measurements past mitral valve prostheses in a model left ventricle. J. Biomech. 24(7), 549-562 (1991).
64. Donea J, Guiliani S, Halleux JP. An arbitrary Lagrangian-Eulerian fnite-element method for transient dynamic fuid structure interactions. Comput. Meth. Appl. Mech. Eng. 33, 689-723 (1982).
65. Baaijens FPT A fctitious domain/mortar element method for fuid-structure interaction. Int. J. Numer. Meth. Fluid. 35, 743-761 (2001).
66. Morsi YS, Yang W W, Wong CS, Das S. Transient fuid-structure coupling for simulation of a trileafet heart valve using weak coupling. J. Artif. Organs 10 (2), 96-103 (2007).
67. Bathe KJ. Non-linear fnite-element analysis and adina. Proceedings of the 3rd Adina Conference. Massachusetts Institute of Technology, Cambridge, MA, USA, 10-12 June 1981. Preface. Computers & Structures 13, R5-R55.
68. Dwyer HA, Matthews PB, Azadani A et al. Computational fuid dynamics simulation of transcatheter aortic valve degeneration. Interact. Cardiovasc. Thorac. Surg. 9(2), 301-308 (2009).
69. Sirois E, Sun W. Computational evaluation of platelet activation induced by a bioprosthetic heart valve. Artif. Organs 35(2), 157-165 (2011).
70. Sun W, Li K, Sirois E. Simulated elliptical bioprosthetic valve deformation: implications for asymmetric transcatheter valve deployment. J. Biomech. 43(16), 3085-3090 (2010).
71. Sun W, Abad A, Sacks MS. Simulated bioprosthetic heart valve deformation under quasi-static loading. J. Biomech. Eng. 127(6), 905-914 (2005).
72. Thubrikar M. The Aortic Valve. CRC Press, FL, USA 221 (1990).
73. Bluestein D, Rambod E, Gharib M. Vortex shedding as a mechanism for free emboli formation in mechanical heart valves. J. Biomech. Eng. 122(2), 125-134 (2000).
74. Sperling C, Fischer M, Maitz MF, Werner C. Blood coagulation on biomaterials requires the combination of distinct activation processes. Biomaterials 30(27), 4447-4456 (2009).
75. Ratner BD. The catastrophe revisited: blood compatibility in the 21st century. Biomaterials 28(34), 5144-5147 (2007).
76. Ratner BD. Biomaterials Science: An Introduction to Materials in Medicine. Elsevier Academic Press, Amsterdam, The Netherlands; Boston, MA, USA, xii, 851 (2004).
77. Michelson AD. Platelets. Academic Press/Elsevier, Amsterdam; Boston, pp xlii, 1343 (2007).
78. Müller F, Renné T. Novel roles for factor XII-driven plasma contact activation system. Curr. Opin. Hematol. 15(5), 516-521 (2008).
79. Schousboe I. Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation. Biochem. Pharmacol. 75(5), 1007-1013 (2008).
80. Gailani D, Renné T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J. Thromb. Haemost. 5(6), 1106-1112 (2007).
81. Bäck J, Sanchez J, Elgue G, Ekdahl KN, Nilsson B. Activated human platelets induce factor XIIa-mediated contact activation. Biochem. Biophys. Res. Commun. 391(1), 11-17 (2010).
82. Jesty J, Bluestein D. Acetylated prothrombin as a substrate in the measurement of the procoagulant activity of platelets: elimination of the feedback activation of platelets by thrombin. Anal Biochem. 272(1), 64-70 (1999).
83. Bae JY, Chung DJ, An JH, Shin DH. Effect of the structure of chain extenders on the dynamic mechanical behaviour of polyurethane. J. Mater. Sci. 34, 2523-2527 (1999).
84. Leo HL, Dasi LP, Carberry J, Simon HA, Yoganathan AP. Fluid dynamic assessment of three polymeric heart valves using particle image velocimetry. Ann. Biomed. Eng. 34(6), 936-952 (2006).
85. Daebritz SH, Fausten B, Hermanns B et al. New fexible polymeric heart valve prostheses for the mitral and aortic positions. Heart Surg. Forum 7(5), E525-E532 (2004).
86. Rahmani B, Tzamtzis S, Ghanbari H, Burriesci G, Seifalian AM. Manufacturing and hydrodynamic assessment of a novel aortic valve made of a new nanocomposite polymer. J. Biomech. 45(7), 1205-1211 (2012).
87. Hernandez R, Weksler J, Padsalgikar A, Runt J. In vitro oxidation of high polydimethylsiloxane content biomedical polyurethanes: correlation with the microstructure. J. Biomed. Mater. Res. A 87(2), 546-556 (2008).
88. Pinchuk L. Crosslinked polyolefns for biomedical applicatios and method of making same. In: USPTO. USPTO, VA, USA (2009).
89. Ding N, Pacetti SD, Tang FW, Gada M, Roorda W. Xience V™ stent design and rationale. J. Interven. Cardiol. 22, S18-S27 (2009).
90. Kalita H, Karak N. Bio-based elastomeric hyperbranched polyurethanes for shape memory application. Iranian Poly. J. 21, 263-271 (2012).
91. Sheng DK, Tan JJ, Liu XD, Wang PX, Yang YM. Effect of organoclay with various organic modifers on the morphological, mechanical, and gas barrier properties of thermoplastic polyurethane/organoclay nanocomposites. J. Mater. Sci. 46, 6508-6517 (2011).
92. Kennedy JP. From thermoplastic elastomers to designed biomaterials. J. Polymer. Sci. Poly. Chem. 43, 2951-2963 (2005).
93. Boden M, Richard R, Schwarz MC, Kangas S, Huibregtse B, Barry JJ. In vitro and in vivo evaluation of the safety and stability of the TAXUS paclitaxel-eluting coronary stent. J. Mater. Sci. Mater. Med. 20(7), 1553-1562 (2009).
94. Arrieta EA, Aly M, Parrish R et al. Clinicopathologic correlations of poly-(styrene-b-isobutylene-b-styrene) glaucoma drainage devices of different internal diameters in rabbits. Ophthalmic Surg. Lasers Imaging 42(4), 338-345 (2011).
95. Gallocher SL, Aguirre AF, Kasyanov V, Pinchuk L, Schoephoerster RT. A novel polymer for potential use in a trileafet heart valve. J. Biomed. Mater. Res. Part B Appl. Biomater. 79(2), 325-334 (2006).
96. El Fray M, Prowans P, Puskas JE, Altstadt V. Biocompatibility and fatigue properties of polystyrene-polyisobutylene-polystyrene, an emerging thermoplastic elastomeric biomaterial. Biomacromolecules. 7(3), 844-850 (2006).
97. Yin W, Gallocher S, Pinchuk L, Schoephoerster RT, Jesty J, Bluestein D. Flow-induced platelet activation in a St. Jude mechanical heart valve, a trileafet polymeric heart valve, and a St. Jude tissue valve. Artif. Organs 29(10), 826-831 (2005).
98. Duraiswamy N, Choksi TD, Pinchuk L, Schoephoerster RT. A phospholipid-modi-fed polystyrene-polyisobutylene-polysty-rene (SIBS) triblock polymer for enhanced hemocompatibility and potential use in artifcial heart valves. J. Biomater. Appl. 23(4), 367-379 (2009).
99. Wang Q, McGoron AJ, Pinchuk L, Schoephoerster RT. A novel small animal model for biocompatibility assessment of polymeric materials for use in prosthetic heart valves. J. Biomed. Mater. Res. A 93(2), 442-453 (2010).
100. Claiborne TE, Girdhar G, Gallocher-Lowe S et al. Thrombogenic potential of Innovia polymer valves versus Carpentier-Edwards Perimount Magna aortic bioprosthetic valves. ASAIO J. 57(1), 26-31 (2011).
101. Gallocher SL. Durability assessment of polymer trileafet valves. ProQuest ETD Collection for FIU (2007).
102. Wang Q, McGoron AJ, Bianco R, Kato Y, Pinchuk L, Schoephoerster RT. In-vivo assessment of a novel polymer (SIBS) trileafet heart valve. J. Heart Valve Dis. 19(4), 499-505 (2010).
103. Claiborne TE, Bluestein D, Schoephoerster RT. Development and evaluation of a novel artifcial catheter-deliverable prosthetic heart valve and method for in vitro testing. Int. J. Artif. Organs 32(5), 262-271 (2009).
104. Leon MB, Smith CR, Mack M et al.; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 363(17), 1597-1607 (2010).
105. Stock UA, Degenkolbe I, Attmann T, Schenke-Layland K, Freitag S, Lutter G. Prevention of device-related tissue damage during percutaneous deployment of tissue-engineered heart valves. J. Thorac. Cardiovasc. Surg 131(6), 1323-1330 (2006).
106. Lutter G, Metzner A, Jahnke T et al Percutaneous tissue-engineered pulmonary valved stent implantation. Ann. Thorac. Surg 89(1), 259-263 (2010).
107. Sochman J, Peregrin JH, Pulda Z et al. A new cone-shaped aortic valve prosthesis for orthotopic position: an experimental study in Swine. Cardiovasc. Intervent. Radiol. 33(2), 330-335 (2010).
108. Platis A, Larson DF. CardioWest tempo rary total artifcial heart. Perfusion 24(5), 341-346 (2009).
109. Jarvik RK. The total artifcial heart. Sci. Am. 244(1), 74-80 (1981).
110. Kolff WJ. An artifcial heart inside the body. Sci. Am. 213(5), 39-46 (1965).
111. Goubergrits L, Leirner A, Affeld K. Trileafet valve for VAD use with purged sinus. Artif Organs 27(6), 586-591 (2003).
112. Roszelle BN, Deutsch S, Manning KB. A parametric study of valve orientation on the fow patterns of the Penn State pulsatile pediatric ventricular assist device. ASAIO J. 56(4), 356-363 (2010).
113. Girdhar G, Bluestein D. Biological effects of dynamic shear stress in cardiovascular pathologies and devices. Expert Rev. Med. Devices 5(2), 167-181 (2008).
114. Girdhar G, Xenos M, Alemu Y et al. Device thrombogenicity emulation: a novel method for optimizing mechanical circulatory support device thromboresistance. PLoS ONE 7(3), e32463 (2012).
115. Xenos M, Girdhar G, Alemu Y et al. Device Thrombogenicity Emulator (DTE)-design optimization methodology for cardiovascular devices: a study in two bileafet MHV designs. J. Biomech. 43(12), 2400-2409 (2010).
116. Xenos M, Girdhar G, Alemu Y et al. Device thrombogenicity emulator (Dte)-design optimization methodology for cardiovascular devices: a study in two bileafet Mhv designs. J. Biomech 43(12), 2400-2409 (2010).
117. Girdhar G, Xenos M, Alemu Y et al. Device thrombogenicity emulation: a novel method for optimizing mechanical circulatory support device thromboresistance. PLoS One 7(3), e32463 (2012).
118. Fishbein MC, Roberts WC, Golden A, Hufnagel CA. Cardiac pathology after aortic valve replacement using Hufnagel trileafet prostheses: a study of 20 necropsy patients. Am. Heart J. 89(4), 443-448 (1975).
119. Clark RE, Swanson WM, Kardos JL, Hagen RW, Beauchamp RA. Durability of prosthetic heart valves. Ann. Thorac. Surg. 26(4), 323-335 (1978).
120. Leat ME, Fisher J. Comparative study of the function of the Abiomed polyurethane heart valve for use in left ventricular assist devices. J. Biomed. Eng. 15(6), 516-520 (1993).
121. Robin J, Martinot S, Curtil A et al. Experimental right ventricle to pulmonary artery discontinuity: outcome of polyurethane valved conduits. J. Thorac. Cardiovasc. Surg. 115 (4), 898-903 (1998).
122. Bernacca GM, Straub I, Wheatley DJ. Mechanical and morphological study of biostable polyurethane heart valve leafets explanted from sheep. J. Biomed. Mater. Res. 61(1), 138-145 (2002).